Literature DB >> 18182220

Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system.

Alvin H Schmaier1.   

Abstract

The plasma kallikrein/kinin system that consists of the proteins factor XII, prekallikrein, and high molecular weight kininogen was first recognized as a surface-activated coagulation system arising when blood or plasma interacts with artificial surfaces. Although surface-activated contact activation occurs in vivo when various negatively charged surfaces become exposed, including a developing platelet thrombus, a physiologic, non-injury mechanism for activation, regulation, and function of this system has been elusive. Recent investigations have shown that there is a physiologic pathway for assembly and activation of this system independent of factor XII. Gene deficient mice of the bradykinin B2 receptor and factor XII have been recognized to have reduced risk for arterial thrombosis. This plasma proteolytic system influences arterial thrombosis independent of influencing hemostasis. Thus, the plasma kallikrein/kinin system has two mechanisms for its activation: one that is dependent and another independent of factor XII. Better understanding of this system may lead to insight into mechanisms for arterial thrombosis, independent of hemostasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18182220      PMCID: PMC2266068          DOI: 10.1016/j.intimp.2007.08.022

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  55 in total

1.  Receptor-mediated internalization of bradykinin. DDT1 MF-2 smooth muscle cells process internalized bradykinin via multiple degradative pathways.

Authors:  C M Munoz; L M Leeb-Lundberg
Journal:  J Biol Chem       Date:  1992-01-05       Impact factor: 5.157

2.  Isolation and characterization of the kininogen-binding protein p33 from endothelial cells. Identity with the gC1q receptor.

Authors:  H Herwald; J Dedio; R Kellner; M Loos; W Müller-Esterl
Journal:  J Biol Chem       Date:  1996-05-31       Impact factor: 5.157

3.  Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R).

Authors:  K Joseph; B Ghebrehiwet; E I Peerschke; K B Reid; A P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

4.  High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation.

Authors:  Y Lin; R B Harris; W Yan; K R McCrae; H Zhang; R W Colman
Journal:  Blood       Date:  1997-07-15       Impact factor: 22.113

5.  Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.

Authors:  R W Colman; R A Pixley; S Najamunnisa; W Yan; J Wang; A Mazar; K R McCrae
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

6.  The expression of high molecular weight kininogen on human umbilical vein endothelial cells.

Authors:  A H Schmaier; A Kuo; D Lundberg; S Murray; D B Cines
Journal:  J Biol Chem       Date:  1988-11-05       Impact factor: 5.157

7.  Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis.

Authors:  J P Loza; V Gurewich; M Johnstone; R Pannell
Journal:  Thromb Haemost       Date:  1994-03       Impact factor: 5.249

8.  High molecular weight kininogen binds to unstimulated platelets.

Authors:  E J Gustafson; D Schutsky; L C Knight; A H Schmaier
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

9.  Plasma membrane-bound and lysosomal peptidases in human alveolar macrophages.

Authors:  H L Jackman; F Tan; D Schraufnagel; T Dragović; B Dezsö; R P Becker; E G Erdös
Journal:  Am J Respir Cell Mol Biol       Date:  1995-08       Impact factor: 6.914

10.  Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells.

Authors:  S R Reddigari; Y Shibayama; T Brunnée; A P Kaplan
Journal:  J Biol Chem       Date:  1993-06-05       Impact factor: 5.157

View more
  27 in total

1.  Plasma prekallikrein levels are positively associated with circulating lipid levels and the metabolic syndrome in children.

Authors:  James A MacKenzie; Kristen A Roosa; Brooks B Gump; Amy K Dumas; Kestutis G Bendinskas
Journal:  Appl Physiol Nutr Metab       Date:  2010-08       Impact factor: 2.665

2.  A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.

Authors:  K-A Steen Burrell; J Layzer; B A Sullenger
Journal:  J Thromb Haemost       Date:  2017-08-02       Impact factor: 5.824

Review 3.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

Review 4.  The initiation and effects of plasma contact activation: an overview.

Authors:  Lisha Lin; Mingyi Wu; Jinhua Zhao
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

5.  Novel mechanism of plasma prekallikrein (PK) activation by vascular smooth muscle cells: evidence of the presence of PK activator.

Authors:  J S Keum; M A Jaffa; L M Luttrell; A A Jaffa
Journal:  J Biol Regul Homeost Agents       Date:  2014 Oct-Dec       Impact factor: 1.711

6.  Limited role of kininogen in the host response during gram-negative pneumonia-derived sepsis.

Authors:  Chao Ding; Cornelis van 't Veer; Joris J T H Roelofs; Meenal Shukla; Keith R McCrae; Alexey S Revenko; Jeff Crosby; Tom van der Poll
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-11-09       Impact factor: 5.464

7.  Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release.

Authors:  Kerstin Göbel; Chloi-Magdalini Asaridou; Monika Merker; Susann Eichler; Alexander M Herrmann; Eva Geuß; Tobias Ruck; Lisa Schüngel; Linda Groeneweg; Venu Narayanan; Tilman Schneider-Hohendorf; Catharina C Gross; Heinz Wiendl; Beate E Kehrel; Christoph Kleinschnitz; Sven G Meuth
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-17       Impact factor: 11.205

Review 8.  Polyphosphate as modulator of hemostasis, thrombosis, and inflammation.

Authors:  J H Morrissey; S A Smith
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

9.  Activation of the contact system at the surface of Fusobacterium necrophorum represents a possible virulence mechanism in Lemièrre's syndrome.

Authors:  Karin Holm; Inga-Maria Frick; Lars Björck; Magnus Rasmussen
Journal:  Infect Immun       Date:  2011-06-06       Impact factor: 3.441

10.  Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein.

Authors:  Karim Abid; Bertrand Rochat; Paul-Gerhard Lassahn; Reto Stöcklin; Sophie Michalet; Noureddine Brakch; Jean-Francois Aubert; Bilgin Vatansever; Patricia Tella; Ingrid De Meester; Eric Grouzmann
Journal:  J Biol Chem       Date:  2009-07-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.